Cystic Fibrosis

mul1TGV Therapeutics’ lead product is a nebulized Mul-1867-CF solution designed for convenient self-administration.  Mul-1867-CF (original nano-sized molecule 1.5-2.0 nm) the first inhaled antimicrobial being developed against multidrug-resistant bacteria and fungi and will be the breakthrough in war with lung infections in patients with cystic fibrosis.

Mul-1867-CF target biofilm-associated infections in the lungs of CF caused by P.aeruginosa, S.aureus, B.cepacia, H.influenzae, Aspergillus spp., Candida spp., etc.

By delivering drug directly to the sites of pulmonary infection, Mul-1867-CF demonstrates clinical efficacy and safety.

TGV-Therapeutics recently completed first-in-human pilot study of Mul-1867-CF in 15 cystic fibrosis patients during pulmonary exacerbation (outside the US).

Mul-1867-CF

provides treatment and protection that is:

  • More effective (no microorganisms are resistant to Mul-1867-CF)
  • Penetrate biofilms
  • Faster
  • Active against antibiotic-resistant strains 

across all bacteria and fungi

Learn More About Lung Infections in CF Subjects